Innovators in Cancer Immunology: Ovarian Cancer
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Innovators in Cancer Immunology: Ovarian Cancer

June 20, 2017

Innovators in Cancer Research: Ovarian Cancer


Michael Feldman, MD, PhD
Associate Professor of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania Philadelphia, PA

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. Michael Feldman is a longtime thought leader in the drive to modernize pathology. He has been actively integrating image analysis, algorithms, digital imaging technology, and informatics to address the shortcoming of conventional immunohistochemistry (IHC) and visual perception. Dr. Feldman is an early adopter of PerkinElmer’s Phenoptics technology, and today is focusing on merging quantitative pathology approaches with digital pathology platforms, workflows, and laboratory information systems., Dr. Feldman most recently used Phenoptics imaging capabilities to automate the challenging visual task of assessing TIL counts on conventional, 3-color,chromogenic immunohistochemistry (IHC) instrument.

Read More Stories Like This One

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the A...

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...

Innovators in Cancer Immunology: Lung Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this i...